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REPLY: Does Size Matter?In Search of a Physiological Deﬁnition of
Myocardial AtrophyWe would like to thank Dr. Terraciano and col-
leagues for their interest in our study (1). The aim of
our study was to: 1) address the long-standing issue
of whether myocardial atrophy and degeneration
could be induced as a result of prolonged ventricu-
lar assist device (VAD) unloading; and 2) address
this issue by studying the effects of newer genera-
tion, continuous-ﬂow VADs. Previous studies that
used ﬁrst-generation pulsatile VADs reported effects
on myocardial hypertrophy (2). These studies did
not focus on investigating myocardial atrophy and
degeneration.
One aspect of our research approach was to deﬁne
and try to identify atrophy pathologically both at the
cellular and subcellular levels using digital histopa-
thology, confocal microscopy, and electron micro-
scopic analysis (methodologies thatwere standardized
in previous publications from our group). Our ex vivo
structural data were also supported by the in vivo
echocardiographic data, which showed no left ven-
tricular (LV) mass reduction to levels lower than the
normal range and no LV function decline indicative
of atrophy and degeneration. Along the same lines, we
did not observe metabolic changes (e.g., excessive
glycogen accumulation) that would have been an
indication of atrophic remodeling.
Regarding the t-tubule microstructural analysis,
we agree with Dr. Teracciano and colleagues that our
approach is a starting point in the quest to under-
stand remodeling in VAD patients at the subcellular
level. Based on our recent work, we think that the
applied t-tubule–ryanodine receptor relationship is
a powerful concept for characterizing the t-system
and associated functional remodeling. Speciﬁcally,
we introduced the t-tubule–RyR relationship as aquantitative marker of subcellular structural remod-
eling of the failing heart and restoration after cardiac
resynchronization therapy (3). In our recent study on
local depletion of the t-system in ventricular myo-
cytes, we found that this structural marker could
also help explain deﬁciencies in excitation–contrac-
tion coupling (4). These studies motivated us to
apply this marker in the investigations on the
myocardial tissue from VAD patients. Unlike the
disruption of the t-tubule system that was observed
by Ibrahim et al. (5) in rat hearts that were fully
unloaded (and denervated) after heterotopic trans-
plantation, in the case of the partial unloading
induced by VADs, we did not observe any t-tubule
system changes that would indicate atrophic
remodeling. As shown by Ibrahim et al. (5) in their
rodent model, “the degree of atrophy depends on the
degree of unloading.” The major differences in the
degree of unloading between the heterotopic trans-
plantation model and the VAD-induced unloading
could explain the differential results. Also, the het-
erotopically transplanted rat hearts had a heart fail-
ure (HF) history of only 4 weeks versus the
chronically ill human hearts of end-stage VAD pa-
tients, which could have also played a role in the
differential response.
In an effort to investigate whether signaling path-
ways associated with atrophic remodeling were acti-
vated, we performed an extensive molecular analysis.
We did not ﬁnd any gene and protein expression
changes that were indicative of active atrophic
remodeling. We acknowledge that these pathways are
complex and not only associated with atrophic
remodeling. For this reason, we did not interpret the
molecular data as isolated evidence, but we did inter-
pret it in conjunction with the structural, t-system
microstructural, ultrastructural, metabolic, and echo-
cardiographic functional phenotypes.
We also analyzed tissue specimens from 18 normal
donor human hearts, and we believe this is one of the
strengths of our study, which has seldom been seen
in similar investigations due to a lack of available
normal heart tissue. In our study, the myocardial
structural analysis that was central for this investi-
gation was performed in this sizeable cohort of
normal donor heart specimens and in the remaining
assays in as many normal heart samples as feasible.
We strongly agree that our data must not be used as
an indication of normalization of cardiac function.
The aim of this study was to investigate whether VAD-
induced unloading could be detrimental and lead to
atrophic remodeling and degeneration. We included
patients who were unloaded with continuous-ﬂow
VAD for up to 1 year, and the evidence presented
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unloading was not associated with atrophy and
degeneration. We therefore suggest that pharmaco-
logical strategies to prevent atrophy might not be the
best way to enhance the cardiac recovery associated
with VAD unloading. We would like to emphasize
that the aim of this study was not to investigate:
1) the incidence, magnitude, and time course of the
functional cardiac recovery, and 2) the associated
mechanisms. These aspects are being examined in
ongoing investigations carried out by our group
and others.
We also agree that regression of hypertrophy is
only 1 of the aspects of reverse cardiac remodeling
and cannot be directly linked to functional cardiac
recovery (2). However, we do not agree that the
indisputable fact that most human failing hearts do
not recover after VAD unloading should direct on
mechanistic investigations to enhance the phenome-
non of unloading-induced recovery toward a search
for a “physiological deﬁnition of myocardial atro-
phy.” We feel that biomarkers derived from the sub-
set of HF patients that respond favorably to VAD
unloading could redirect the basic science studies
of cardiac recovery by identifying pathways rele-
vant to humans. The ﬁndings of these in-
vestigations could lead to new therapeutic targets
that could be tested in our HF patients with clin-
ical comparative effectiveness studies.Nikolaos A. Diakos, MD
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